Sara Al-Zubeidi
Director, Commercial Strategy Consulting Global Pricing and Market Access
Sara Al-Zubeidi is a Director with Clarivate based in London. Sara has 7+ years commercial strategy consulting experience in life sciences, specializing in global pricing and market access.
Sara leads teams for global P&MA engagements on behalf of pharmaceutical and biotechnology companies. Areas of expertise include pricing and access strategy, evidence generation for HTA submission, innovative agreement strategy, HTA landscape analysis, analogue assessments, value proposition/story development and payer objection handling/negotiation tactics. She also has extensive experience in commercial opportunity assessments, including indication and opportunity prioritization and patient flow assessments. Sara has deep expertise across a wide span of therapeutic areas with oncology, orphan/rare diseases, cardiology, renal and metabolic diseases as specialist areas of interest.
Prior to joining consulting, Sara worked in business development specifically for HEOR and Evidence Strategy teams.
Sara has a Master’s degree in Pharmacogenetics and Stratified Medicine at University College of London (UCL) and a BSc (Hons) in Medical Genetics from Queen Mary University of London.
Latest news
Clarivate Expands Access to Trusted Regulatory Intelligence Within Claude
Advancing Clarivate strategy to extend proprietary intelligence into enterprise AI ecosystems Bringing Clarivate domain-specific regulatory insights into Claude to support life sciences workflows LONDON, U.K, March 10, 2026 Clarivate Plc…
National Research Council of Italy Joins Early Adopter Cohort for Web of Science Research Intelligence
London, U.K. March 9, 2026: Consiglio Nazionale delle Ricerche (CNR), the National Research Council of Italy, has joined the early adopter program for Web of Science Research Intelligence from Clarivate,…
Clarivate Library Innovation Awards Reveal the 2026 Finalists
An independent judging panel selected finalists who demonstrated exceptional creativity, innovation and impact London, U.K. March 5, 2026. Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced…